Back to results
US 2014/0369977 A1Published application
Targeting Tumor Neovasculature with Modified Chimeric Antigen Receptors
AssigneeUniversity of Houston System
InventorsXiaoliu Zhang, Xinping Fu
Life of this patent
Estimating the term…
Abstract
A T cell transduced with a chimeric antigen receptor can be administered to a host to kill cancer cells. The chimeric antigen receptor can include a targeting moiety with a strong binding affinity to αvβ3 integrin, including but not limited to an echistatin polypeptide. The targeting moiety can also be modified to have a reduced binding affinity to α5β1 integrin.
Claims20
A compound for killing cancer cells comprising:
- a T-cell engrafted with a chimeric antigen receptor (CAR), wherein the CAR comprises a targeting moiety that has a strong binding affinity to αvβ3 integrin.
A method for engrafting T cells with a chimeric antigen receptor (CAR) comprising:
- transducing T cells with a retroviral vector or lentiviral vector, the retro- or lentiviral vector comprising coding sequences for a T cell zeta chain and a targeting moiety that has a strong binding affinity to αvβ3 integrin.
A method of killing cancer cells in a host comprising:
- administering to the host T cells transduced with a chimeric antigen receptor (CAR), the CAR comprising a targeting moiety that has a strong binding affinity to αvβ3 integrin.
Dependencies are inferred from the claim text.